We are live on ! Find out more
ENZY

Enzymotec Ltd
ENZY

Delisted

ENZY was delisted on the 10th of January, 2018.

Back to rankings

37 hedge funds and large institutions have $97.1M invested in Enzymotec Ltd in 2017 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 8

138% more capital invested

Capital invested by funds: $40.7M → $97.1M (+$56.4M)

85% more funds holding

Funds holding: 20 → 37 (+17)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

Holders
37
Holders Change
+17
Holders Change %
+85%
% of All Funds
0.84%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
3
Reduced
4
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
GF
Gabelli Funds
New York
+$6.69M
2
GH
GAM Holding
Switzerland
+$6.15M
3
WIC
Water Island Capital
New York
+$4.64M
4
WRBC
W.R. Berkley Corp
Connecticut
+$3.2M
5
Renaissance Technologies
Renaissance Technologies
New York
+$3.07M

Top Sellers

1
TM
Tiger Management
New York
-$7.76M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$458K
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$331K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$207K
5
CS
Credit Suisse
Switzerland
-$184K
Name Holding Trade Value Shares
Change 		Change in
Stake
WAM
26
Wolverine Asset Management
Illinois
$138K +$136K +11,700 New
SIM
27
Spark Investment Management
New York
$136K +$133K +11,500 New
Geode Capital Management
28
Geode Capital Management
Massachusetts
$130K – – –
Citadel Advisors
29
Citadel Advisors
Florida
$126K +$123K +10,623 New
SG Americas Securities
30
SG Americas Securities
New York
$116K +$114K +9,800 New
JP Morgan Chase
31
JP Morgan Chase
New York
$79K -$30.7K -2,643 -28%
VanEck Associates
32
VanEck Associates
New York
$41K -$31.4K -2,704 -44%
Wells Fargo
33
Wells Fargo
California
$33K +$32.4K +2,790 New
Macquarie Group
34
Macquarie Group
Australia
$26K +$25.5K +2,200 New
TRCT
35
Tower Research Capital (TRC)
New York
$12K -$84.1K -7,248 -87%
Bank of America
36
Bank of America
North Carolina
$5K – – –
TM
37
Tiger Management
New York
– -$7.76M -677,548 Closed
T. Rowe Price Associates
38
T. Rowe Price Associates
Maryland
– -$458K -166,445 Closed
Fidelity Investments
39
Fidelity Investments
Massachusetts
– -$331K -28,900 Closed
Acadian Asset Management
40
Acadian Asset Management
Massachusetts
– -$207K -17,913 Closed
CS
41
Credit Suisse
Switzerland
– -$184K -16,096 Closed
GP
42
GLG Partners
United Kingdom
– -$184K -16,096 Closed
LCM
43
Laurion Capital Management
New York
– -$134K -11,732 Closed
UBS Group
44
UBS Group
Switzerland
– -$22K -1,935 Closed
KAM
45
Kassirer Asset Management
Ontario, Canada
– +$2.56M +220,800 New
1
2

ENZY Hedge Fund Activity: Q4 2017 in Review

37 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Enzymotec Ltd (ENZY) for Q4 2017, worth a combined $97.1M — up 138% from $40.7M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new ENZY positions and 8 closed out — a net gain of 17 holders — while 3 added to existing stakes and 4 trimmed.

The largest buyer was Gabelli Funds, opening a new position worth an estimated $6.69M. The largest seller was Tiger Management, exiting entirely with an estimated $7.76M sold.

  • 37 institutional investors held Enzymotec Ltd (ENZY) as of Q4 2017, up from 20 in Q3 2017.
  • Funds reported $97.1M of Enzymotec Ltd stock for Q4 2017, up 138% quarter-over-quarter.
  • 25 funds opened new Enzymotec Ltd positions in Q4 2017 and 8 closed out, a net change of +17 holders.
  • The largest Enzymotec Ltd buyer in Q4 2017 was Gabelli Funds, an estimated $6.69M added.
  • The largest Enzymotec Ltd seller in Q4 2017 was Tiger Management, an estimated $7.76M sold.

Based on aggregated 13F filings for Q4 2017.